e-ISSN: Pending
Negative / Null Result ReportOpen accessMedicine· cited by 14

Integrating Artificial Intelligence and PET Imaging for Drug Discovery: A Paradigm Shift in Immunotherapy

Jeremy McGale; Harrison J. Howell; Arnaud Beddok; Mickaël Tordjman; Roger Sun; Delphine L. Chen; Anna M. Wu; Tarek Assi · 2024 · Pharmaceuticals

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

The integration of artificial intelligence (AI) and positron emission tomography (PET) imaging has the potential to become a powerful tool in drug discovery. This review aims to provide an overview of the current state of research and highlight the potential for this alliance to advance pharmaceutical innovation by accelerating the development and deployment of novel therapeutics. We previously performed a scoping review of three databases (Embase, MEDLINE, and CENTRAL), identifying 87 studies published between 2018 and 2022 relevant to medical imaging (e.g., CT, PET, MRI), immunotherapy, arti

Abstract by Jeremy McGale; Harrison J. Howell; Arnaud Beddok; Mickaël Tordjman; Roger Sun; Delphine L. Chen; Anna M. Wu; Tarek Assi, Pharmaceuticals (2024) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.3390/ph17020210